USSN: 10/782,596

AMENDMENTS TO THE CLAIMS:

Please amend the claims as shown below. A complete listing of the claims, including their current status, is set forth below.

1-4. (Canceled)

- 5. (Currently amended) A method for identifying one or more candidate compounds as an agonist, partial agonist, or inverse agonist of a G protein-coupled receptor comprising the polypeptide of SEQ ID NO:20, comprising the steps of:
- (a) contacting said one or more compounds with a host cell comprising said receptor or with a host cell membrane that comprises said receptor; [[and]]
- (b) measuring the ability of the compound or compounds to inhibit or stimulate said receptor; and
- (c) identifying the compound or compounds that inhibit or stimulate said receptor as an agonist, partial agonist, or inverse agonist of said receptor.
- 6. (Original) The method of claim 5 wherein said host cell comprises an expression vector, said expression vector comprising a polynucleotide encoding a G protein-coupled receptor, said receptor comprising the polypeptide of SEQ ID NO:20.
- 7. (Currently amended) A method for identifying one or more candidate compounds as an agonist, partial agonist, or inverse agonist of a G protein-coupled receptor consisting of the polypeptide of SEQ ID NO:20, comprising the steps of:
- (a) contacting said one or more compounds with a host cell comprising said receptor or with a host cell membrane that comprises said receptor; [[and]]
- (b) measuring the ability of the compound or compounds to inhibit or stimulate said receptor; and
- (c) identifying the compound or compounds that inhibit or stimulate said receptor as an agonist, partial agonist, or inverse agonist of said receptor.

USSN: 10/782,596

8. (Previously presented) The method of claim 7 wherein said host cell comprises an expression vector, said expression vector comprising a polynucleotide encoding a G protein-coupled receptor, said receptor consisting of the polypeptide of SEQ ID NO:20.

9-20 (Canceled)

- 21. (Currently amended) A method for identifying one or more candidate compounds as an agonist, partial agonist, or inverse agonist of a G protein-coupled receptor comprising the polypeptide of SEQ ID NO:20, wherein the glycine at amino acid position 285 of SEQ ID NO:20 is substituted with an amino acid other than glycine, comprising the steps of:
- (a) contacting said one or more compounds with a host cell comprising said receptor or with a host cell membrane that said receptor; [[and]]
- (b) measuring the ability of the compound or compounds to inhibit or stimulate said receptor; **and**
- (c) identifying the compound or compounds that inhibit or stimulate said receptor as an agonist, partial agonist, or inverse agonist of said receptor.
- 22. (Original) The method of claim 21 wherein the glycine at amino acid position 285 is substituted with lysine.
- 23. (Original) The method of claim 21 wherein said host cell comprises an expression vector, said expression vector comprising a polynucleotide encoding a G protein-coupled receptor comprising the polypeptide of SEQ ID NO:20, wherein the glycine at amino acid position 285 of SEQ ID NO:20 is substituted with an amino acid other than glycine.
- 24. (Currently amended) A method for identifying one or more candidate compounds as an agonist, partial agonist, or inverse agonist of a G protein-coupled receptor consisting of the polypeptide of SEQ ID NO:20, wherein the glycine at amino acid position 285 of SEQ ID NO:20 is substituted with an amino acid other than glycine, comprising the steps of:

USSN: 10/782,596

(a) contacting said one or more compounds with a host cell comprising said receptor or with a host cell membrane that comprises said receptor; [[and]]

- (b) measuring the ability of the compound or compounds to inhibit or stimulate of said receptor; and
- (c) identifying the compound or compounds that inhibit or stimulate said receptor as an agonist, partial agonist, or inverse agonist of said receptor.
- 25. (Original) The method of claim 24 wherein the glycine at amino acid position 285 is substituted with lysine.
- 26. (Original) The method of claim 24 wherein said host cell comprises an expression vector, said expression vector comprising a polynucleotide encoding a G protein-coupled receptor consisting of the polypeptide of SEQ ID NO:20, wherein the glycine at amino acid position 285 of SEQ ID NO:20 is substituted with an amino acid other than glycine.

27. (Canceled)

- 28. (Currently amended) A method for identifying one or more candidate compounds as an agonist, partial agonist, or inverse agonist of a G protein-coupled receptor consisting of the polypeptide of SEQ ID NO:20 or an endogenous version thereof which is encoded by a polynucleotide that hybridizes under stringent conditions to the complement of SEQ ID NO:19, wherein said stringent conditions comprise a wash at 65°C in 0.1xSSC, comprising the steps of:
- (a) contacting said one or more compounds with a host cell comprising said receptor or with a host cell membrane that comprises said receptor; [[and]]
- (b) measuring the ability of the compound or compounds to inhibit or stimulate said receptor; and
- (c) identifying the compound or compounds that inhibit or stimulate said receptor as an agonist, partial agonist, or inverse agonist of said receptor.

USSN: 10/782,596

29. (Currently amended) A method for identifying one or more candidate compounds as an agonist, partial agonist, or inverse agonist of a G protein-coupled receptor consisting of the polypeptide of SEQ ID NO:20 or an endogenous version thereof which is encoded by a polynucleotide that hybridizes under stringent conditions to the complement of SEQ ID NO:19, wherein said stringent conditions comprise a wash at 65°C in 0.1xSSC, comprising the steps of:

- (a) contacting said one or more compounds with a host cell comprising said receptor or with a host cell membrane that comprises said receptor; [[and]]
- (b) measuring the ability of the compound or compounds to inhibit or stimulate said receptor; **and**
- (c) identifying the compound or compounds that inhibit or stimulate said receptor as an agonist, partial agonist, or inverse agonist of said receptor.
- 30. (Previously presented) A method according to any one of claims 5, 8, 21 to 26, 28 and 29, wherein the method further comprises formulating said agonist, partial agonist, or inverse agonist as a pharmaceutical.